Yifan Pharmaceutical Valuation
Is 002019 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 002019 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 002019 (CN¥11.85) is trading above our estimate of fair value (CN¥3.18)
Significantly Below Fair Value: 002019 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 002019?
Key metric: As 002019 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 002019's PS Ratio? | |
|---|---|
| PS Ratio | 2.9x |
| Sales | CN¥5.00b |
| Market Cap | CN¥14.41b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.2x |
| Enterprise Value/EBITDA | 36.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 002019's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6x | ||
600129 Chongqing Taiji Industry(Group)Ltd | 1x | 12.6% | CN¥14.3b |
000766 Tonghua Golden-Horse Pharmaceutical Industry CoLtd | 9.3x | n/a | CN¥13.9b |
688166 BrightGene Bio-Medical Technology | 10.9x | 26.5% | CN¥13.5b |
603456 Zhejiang Jiuzhou Pharmaceutical | 2.7x | 12.0% | CN¥13.3b |
002019 Yifan Pharmaceutical | 2.9x | 16.0% | CN¥14.4b |
Price-To-Sales vs Peers: 002019 is good value based on its Price-To-Sales Ratio (2.9x) compared to the peer average (6x).
Price to Sales Ratio vs Industry
How does 002019's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
600664 Harbin Pharmaceutical Group | 0.6x | n/a | US$1.34b |
000411 Zhejiang Int'l GroupLtd | 0.2x | n/a | US$803.85m |
600781 FUREN Group PharmaceuticalLtd | 0.3x | n/a | US$66.91m |
002435 Changjiang Runfa Health Industry | 0.2x | n/a | US$63.75m |
| 5 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 002019 is good value based on its Price-To-Sales Ratio (2.9x) compared to the CN Pharmaceuticals industry average (3.7x).
Price to Sales Ratio vs Fair Ratio
What is 002019's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.9x |
| Fair PS Ratio | 4.3x |
Price-To-Sales vs Fair Ratio: 002019 is good value based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (4.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Dong-E-E-JiaoLtd
CN¥37.2b
Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.
423
CN¥57.93
7D
2.3%
1Y
13.8%
China Resources Sanjiu Medical & Pharmaceutical
CN¥57.9b
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
999
CN¥45.11
7D
-1.3%
1Y
19.5%
China Resources Double-Crane PharmaceuticalLtd
CN¥21.9b
China Resources Double-Crane Pharmaceutical Co.,Ltd.
600062
CN¥21.32
7D
2.5%
1Y
10.5%